false 0001656634 --12-31 0001656634 2021-05-03 2021-05-03

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 3, 2021

 

 

Gritstone bio, Inc.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   001-38663   47-4859534

(State or other jurisdiction

of incorporation)

 

(Commission

File Number)

 

(IRS Employer

Identification Number)

 

5959 Horton Street, Suite 300
Emeryville, California 94608
(Address of principal executive offices, including Zip Code)

Registrant’s telephone number, including area code: (510) 871-6100

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading

Symbol(s)

 

Name of each exchange

on which registered

Common Stock, par value $0.0001   GRTS   The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company  

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  

 

 

 


Item 5.03

Amendments to Articles of Incorporation or Bylaws; Chang in Fiscal Year.

On May 3, 2021, Gritstone Oncology, Inc. (the “Company”) changed its name to Gritstone bio, Inc. The name change was made pursuant to Section 242 of the Delaware General Corporation Law. In connection with the name change, the Company filed a Certificate of Amendment to its Amended and Restated Certificate of Incorporation and amended its bylaws to give effect to the name change.

 

Item 9.01

Financial Statements and Exhibits

(d)    Exhibits

 

Exhibit
No.
  

Description

  3.1    Certificate of Amendment to Amended and Restated Certificate of Incorporation
  3.2    Amended and Restated Bylaws
 104    Cover Page Interactive Data File (embedded within the Inline XBRL document)


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

    Gritstone bio, Inc.
Date: May 5, 2021     By:  

/s/ Andrew Allen

      Andrew Allen
      President and Chief Executive Officer